{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:34:37Z","timestamp":1792373677525,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01492-0","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:18:01Z","timestamp":1779718681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trend of Adjuvant Radiation in Resected Pancreatic Ductal Adenocarcinoma: Evaluation of RTOG 0848 with a Large National Database"],"prefix":"10.1007","volume":"57","author":[{"given":"Erin M.","family":"Dickey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Blansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"11","key":"1492_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.Can-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-0155.","journal-title":"Cancer Res"},{"issue":"3","key":"1492_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1124\/jpet.118.255786","volume":"370","author":"F Lei","year":"2019","unstructured":"Lei F, Xi X, Batra SK, Bronich TK. Combination therapies and drug delivery platforms in combating pancreatic cancer. J Pharmacol Exp Ther. 2019;370(3):682\u201394. https:\/\/doi.org\/10.1124\/jpet.118.255786.","journal-title":"J Pharmacol Exp Ther"},{"issue":"21","key":"1492_CR3","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1200\/jco.2016.67.5553","volume":"34","author":"AA Khorana","year":"2016","unstructured":"Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(21):2541\u201356. https:\/\/doi.org\/10.1200\/jco.2016.67.5553.","journal-title":"J Clin Oncol"},{"key":"1492_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.695627","volume":"11","author":"A Pappalardo","year":"2021","unstructured":"Pappalardo A, Giunta EF, Tirino G, Pompella L, Federico P, Daniele B, et al. Adjuvant treatment in pancreatic cancer: shaping the future of the curative setting. Front Oncol. 2021;11:695627. https:\/\/doi.org\/10.3389\/fonc.2021.695627.","journal-title":"Front Oncol"},{"key":"1492_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1060885","author":"M Malla","year":"2023","unstructured":"Malla M, Fekrmandi F, Malik N, Hatoum H, George S, Goldberg RM, et al. The evolving role of radiation in pancreatic cancer. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2022.1060885.","journal-title":"Front Oncol"},{"issue":"1","key":"1492_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-025-01185-0","volume":"56","author":"CN Kersch","year":"2025","unstructured":"Kersch CN, Grossberg AJ. Perioperative radiation for patients with resectable pancreatic cancer: an updated review after the initial RTOG 0848 results. J Gastrointest Cancer. 2025;56(1):70. https:\/\/doi.org\/10.1007\/s12029-025-01185-0.","journal-title":"J Gastrointest Cancer"},{"issue":"6","key":"1492_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1097\/sla.0000000000003770","volume":"274","author":"O Moaven","year":"2021","unstructured":"Moaven O, Clark CJ, Russell GB, Votanopoulos KI, Howerton R, Levine EA, et al. Optimal adjuvant treatment approach after upfront resection of pancreatic cancer: revisiting the role of radiation based on pathologic features. Ann Surg. 2021;274(6):1058\u201366. https:\/\/doi.org\/10.1097\/sla.0000000000003770.","journal-title":"Ann Surg"},{"issue":"5","key":"1492_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jamcollsurg.2008.12.020","volume":"208","author":"NB Merchant","year":"2009","unstructured":"Merchant NB, Rymer J, Koehler EA, Ayers GD, Castellanos J, Kooby DA, et al. Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg. 2009;208(5):829\u201338. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2008.12.020.","journal-title":"J Am Coll Surg"},{"issue":"10","key":"1492_CR9","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/cncr.23047","volume":"110","author":"L Hazard","year":"2007","unstructured":"Hazard L, Tward JD, Szabo A, Shrieve DC. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: Results of a study from the surveillance, epidemiology, and end results (SEER) registry data. Cancer. 2007;110(10):2191\u2013201. https:\/\/doi.org\/10.1002\/cncr.23047.","journal-title":"Cancer"},{"key":"1492_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.651671","author":"X Shi","year":"2021","unstructured":"Shi X, Peng J, Jiang H, Gao Y, Wang W, Zhou F. Impact of adjuvant chemoradiotherapy on survival of resected pancreatic adenocarcinoma cancer: A surveillance, epidemiology and end results (SEER) analysis. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.651671.","journal-title":"Front Oncol"},{"issue":"12","key":"1492_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243170","volume":"15","author":"Z-B Lin","year":"2020","unstructured":"Lin Z-B, Song J-Y, Li A-C, Chen C, Huang X-X, Xu B-H. The benefit of adjuvant radiotherapy on overall survival in resected stage I to II pancreatic cancer: A propensity-adjusted analysis. PLoS One. 2020;15(12):e0243170. https:\/\/doi.org\/10.1371\/journal.pone.0243170.","journal-title":"PLoS One"},{"issue":"11","key":"1492_CR12","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/cncr.24269","volume":"115","author":"KA Vanderveen","year":"2009","unstructured":"Vanderveen KA, Chen SL, Yin D, Cress RD, Bold RJ. Benefit of postoperative adjuvant therapy for pancreatic cancer. Cancer. 2009;115(11):2420\u20139. https:\/\/doi.org\/10.1002\/cncr.24269.","journal-title":"Cancer"},{"issue":"23","key":"1492_CR13","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1002\/cncr.29652","volume":"121","author":"CE Rutter","year":"2015","unstructured":"Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base. Cancer. 2015;121(23):4141\u20139. https:\/\/doi.org\/10.1002\/cncr.29652.","journal-title":"Cancer"},{"issue":"3","key":"1492_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/sla.0000000000003242","volume":"273","author":"SK Kamarajah","year":"2021","unstructured":"Kamarajah SK, Sonnenday CJ, Cho CS, Frankel TL, Bednar F, Lawrence TS, et al. Association of adjuvant radiotherapy with survival after margin-negative resection of pancreatic ductal adenocarcinoma: A propensity-matched National Cancer Database (NCDB) analysis. Ann Surg. 2021;273(3):587\u201394. https:\/\/doi.org\/10.1097\/sla.0000000000003242.","journal-title":"Ann Surg"},{"issue":"8","key":"1492_CR15","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1245\/s10434-024-15157-4","volume":"31","author":"O Franklin","year":"2024","unstructured":"Franklin O, Sugawara T, Ross RB, Rodriguez Franco S, Colborn K, Karam S, et al. Adjuvant chemotherapy with or without radiotherapy for resected pancreatic cancer after multiagent neoadjuvant chemotherapy. Ann Surg Oncol. 2024;31(8):4966\u201375. https:\/\/doi.org\/10.1245\/s10434-024-15157-4.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1492_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/coc.0000000000000633","volume":"43","author":"RA Abrams","year":"2020","unstructured":"Abrams RA, Winter KA, Safran H, Goodman KA, Regine WF, Berger AC, et al. Results of the NRG Oncology\/RTOG 0848 adjuvant chemotherapy question\u2014Erlotinib+Gemcitabine for resected cancer of the pancreatic head: A Phase II randomized clinical trial. Am J Clin Oncol. 2020;43(3):173\u20139. https:\/\/doi.org\/10.1097\/coc.0000000000000633.","journal-title":"Am J Clin Oncol"},{"issue":"16_suppl","key":"1492_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4005","volume":"42","author":"RA Abrams","year":"2024","unstructured":"Abrams RA, Winter KA, Goodman KA, Regine W, Safran H, Berger AC, et al. NRG Oncology\/RTOG 0848: results after adjuvant chemotherapy +\/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). J Clin Oncol. 2024;42(16_suppl):4005. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4005.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1492_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jso.10320","volume":"85","author":"DP Winchester","year":"2004","unstructured":"Winchester DP, Stewart AK, Bura C, Jones RS. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004;85(1):1\u20133. https:\/\/doi.org\/10.1002\/jso.10320.","journal-title":"J Surg Oncol"},{"issue":"9","key":"1492_CR19","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jama.299.9.1019","volume":"299","author":"WF Regine","year":"2008","unstructured":"Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019\u201326. https:\/\/doi.org\/10.1001\/jama.299.9.1019.","journal-title":"JAMA"},{"issue":"2","key":"1492_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ijrobp.2010.11.039","volume":"82","author":"RA Abrams","year":"2012","unstructured":"Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704\u2014a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012;82(2):809\u201316. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.11.039.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1492_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jss.2020.09.009","volume":"259","author":"LK Winer","year":"2021","unstructured":"Winer LK, Cortez AR, Ahmad SA, Wima K, Olowokure O, Latif T, et al. Evaluating the impact of ESPAC-1 on shifting the paradigm of pancreatic cancer treatment. J Surg Res. 2021;259:442\u201350. https:\/\/doi.org\/10.1016\/j.jss.2020.09.009.","journal-title":"J Surg Res"},{"issue":"12","key":"1492_CR22","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200\u201310. https:\/\/doi.org\/10.1056\/NEJMoa032295.","journal-title":"N Engl J Med"},{"issue":"10","key":"1492_CR23","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/s1470-2045(25)00363-8","volume":"26","author":"QP Janssen","year":"2025","unstructured":"Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, et al. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Lancet Oncol. 2025;26(10):1346\u201356. https:\/\/doi.org\/10.1016\/s1470-2045(25)00363-8.","journal-title":"Lancet Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01492-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01492-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01492-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:18:02Z","timestamp":1779718682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01492-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1492"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01492-0","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}